Last reviewed · How we verify
Fludarabine Phosphate — Competitive Intelligence Brief
marketed
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Fludarabine Phosphate (FLUDARABINE) — Genzyme Corp. Fludarabine works by interfering with DNA synthesis, thereby inhibiting cancer cell growth and proliferation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fludarabine Phosphate TARGET | FLUDARABINE | Genzyme Corp | marketed | 2007-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fludarabine Phosphate CI watch — RSS
- Fludarabine Phosphate CI watch — Atom
- Fludarabine Phosphate CI watch — JSON
- Fludarabine Phosphate alone — RSS
Cite this brief
Drug Landscape (2026). Fludarabine Phosphate — Competitive Intelligence Brief. https://druglandscape.com/ci/fludarabine. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab